Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Receives Average Rating of “Moderate Buy” from Brokerages

Shares of Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) have received a consensus recommendation of “Moderate Buy” from the seven research firms that are covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, four have assigned a buy rating and one has given a strong buy rating to the company. The average 12 month target price among brokerages that have issued ratings on the stock in the last year is $17.50.

A number of research analysts recently weighed in on PHAT shares. Wall Street Zen upgraded shares of Phathom Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Phathom Pharmaceuticals in a research report on Wednesday, October 8th.

Phathom Pharmaceuticals Stock Up 8.1%

Shares of Phathom Pharmaceuticals stock opened at $14.01 on Tuesday. The company has a market cap of $993.87 million, a price-to-earnings ratio of -2.96 and a beta of 0.43. The company’s 50 day moving average is $11.78 and its 200 day moving average is $8.42. Phathom Pharmaceuticals has a twelve month low of $2.21 and a twelve month high of $19.50.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in PHAT. GAMMA Investing LLC raised its position in Phathom Pharmaceuticals by 797.2% in the first quarter. GAMMA Investing LLC now owns 4,558 shares of the company’s stock worth $29,000 after acquiring an additional 4,050 shares during the period. Bank of New York Mellon Corp raised its position in Phathom Pharmaceuticals by 11.5% in the first quarter. Bank of New York Mellon Corp now owns 114,535 shares of the company’s stock worth $718,000 after acquiring an additional 11,787 shares during the period. CWM LLC raised its position in Phathom Pharmaceuticals by 20,997.1% in the first quarter. CWM LLC now owns 7,384 shares of the company’s stock worth $46,000 after acquiring an additional 7,349 shares during the period. Corton Capital Inc. bought a new position in Phathom Pharmaceuticals in the first quarter worth approximately $115,000. Finally, XTX Topco Ltd purchased a new stake in shares of Phathom Pharmaceuticals in the first quarter worth $565,000. 99.01% of the stock is currently owned by institutional investors.

About Phathom Pharmaceuticals

Phathom Pharmaceuticals, Inc, biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach.